AMCP Annual Meeting 2017

About Science & Innovation Theaters

AMCP’s Science & Innovation Theaters provide a structured focus for participants to gain information on specific products, therapeutic areas and/or disease states in presentations provided by company designated presenters.

Each year, industry experts present to an almost sell-out crowd. This year there will be a total of ten (10) Science & Innovation Theaters during the Expo. All Expo hours do not compete with any other official AMCP function to ensure attendees can take full advantage of the different Science & Innovation Theaters.

To host a Science & Innovation Theaters, click here.

Josh Maze
Assistant Director, National Meeting Sales

12:00 pm – 12:30 pm
Theater #1
Clinical and Economic Considerations for the Treatment of Opioid Dependence

Opioid dependence is a serious public health problem throughout the world responsible for substantial morbidity, mortality, and social costs. National guidelines recommend the use of medication-assisted treatment; however, access barriers to these treatments remain for some patients. Join us for a clinical and economic presentation about a medication-assisted treatment option that along with counseling may help treat and reduce overall healthcare costs for opioid dependent patients.

David R. Gastfriend, MD, DFASAM
Scientific Advisor, Treatment Research Institute Chief Architect, CONTINUUM – The ASAM Criteria
Decision Engine™, ASAM Cofounder and Chief Medical Officer, DynamiCare Health™

12:00 pm – 12:30 pm
Theater #2
Amgen, Inc.
Repatha®(evolocumab): A Focused Clinical Review

The Repatha® (evolocumab) mechanism of action will be reviewed, and an overview of safety data will be provided. The program will also review evidence for the efficacy of Repatha® using data from phase 3 randomized, placebo-controlled trials, as well as reviewing Repatha® dosing and administration. A discussion of appropriate patients will be supplemented by relevant case studies.

Richard Mullvain RPh, BCPS (AQC) CCCC
Essentia Health Heart & Vascular Center
Duluth, Minnesota
Cardiovascular Clinical Pharmacist and STEMI Specialist

12:45 pm - 1:45 pm
Theater #1
Boehringer Ingelheim Pharmaceuticals, Inc.
Overview of the New FDA-approved Indication for Jardiance ® (empagliflozin) tablets

In December 2016, the US Food and Drug Administration (FDA) approved a new indication for JARDIANCE. This presentation will share information regarding the clinical findings associated with the new indication. It will also provide an overview of adverse events, warnings and precautions, and use in special populations for JARDIANCE.

Copyright 2017 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (1/17) PC-01572

12:45 pm - 1:15 pm
Theater #2
Amgen, Inc.
Calculations in Cardiovascular Outcome Trials

This presentation will provide an overview of cardiovascular outcome trials and the calculations within these trials.

Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN
Midwest Biomedical Research
Center for Metabolic & Cardiovascular Health
Chicago, IL

1:30 pm - 2:00 pm
Theater #2
Daiichi Sankyo, Inc.
Daiichi Sankyo Pain Trends Report: Evolving Trends in Pain Management

More than 126 million Americans suffer from pain, and it is one of the most common and costly medical conditions in the United States. The pain landscape continues to evolve with the implementation of new therapeutic approaches and policies regarding adequate pain management. To better understand current issues and trends in pain management, Daiichi Sankyo surveyed a broad cross-section of healthcare stakeholders. The results, published in the Pain Trends Report, revealed a variety of perspectives and concerns, including significant unmet needs in pain management.

This presentation provides an overview of current trends in the pain category, the economic burden of pain on healthcare systems, and key findings from the Daiichi Sankyo Pain Trends Report. It will also highlight topics that are likely to shape the future landscape of pain management.
PP-US-PAIN-0069 02/17s

Gary M. Owens, MD
President, Gary Owens Associates
9:45 am - 10:15 am
Theater #1
CSL Behring
Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

Findings from the study using specialty pharmacy data indicate PI patients are switched from IVIg to 20% SCIg at dose ratios lower than the current US recommendations. An analysis of real-world data suggests that patients switching from intravenous immunoglobulin therapy to subcutaneous immunoglobulin (SCIg) therapy while utilizing 20% SCIg realized a post-conversion dose ratio that is approximately 1:1.

Girishanthy Krishnarajah, MPH, MBA/MS, PhD
Senior Director, Global Health Economics & Reimbursement
CSL Behring, LLC

9:45 am - 10:15 am
Theater #2
Takeda Pharmaceuticals USA, Inc.

10:30 am - 11:00 am
Theater #1
Takeda Pharmaceuticals USA, Inc.
The Clinical and Economic Burden of Major Depressive Disorder

A comprehensive disease state review that illustrates the clinical and economic burden and impact of Major Depressive Disorder (MDD). The presentation will highlight MDD, its impact of cognitive symptoms in MDD, the economic burden of depression and related symptoms, in addition to treatment considerations specifically geared to the healthcare payer.

Gustavo Alva, M.D., DFAPA
Distinguished Fellow of the American Psychiatric Association
Diplomate, American Board of Psychiatry and Neurology
Diplomate, American Board of Geriatrics
Medical Director, ATP Clinical Research

10:30 am - 11:00 am
Theater #2
Lexicon Pharmaceuticals
Carcinoid syndrome is rare, misunderstood, and often misdiagnosed. Symptoms often lead to diagnosis of irritable bowel syndrome and other gastrointestinal diseases, resulting in patient suffering and burdensome healthcare costs.

The objectives of the presentation are to:
  •  Communicate patient symptoms and available diagnostics for more timely and accurate diagnosis
  •  Review current standard of care and new treatment modalities
  •  Discuss healthcare costs associated with carcinoid syndrome

Eric Liu, MD
Co-Director, The Neuroendocrine Institute
Rocky Mountain Cancer Centers
Chief Medical Advisor, Healing NET Foundation
Denver, Colorado

© 2017 Academy of Managed Care Pharmacy | 675 North Washington Street, Suite 220, Alexandria, VA 22314 | 703-684-2600 |